Hua Chen to Child
This is a "connection" page, showing publications Hua Chen has written about Child.
Connection Strength
4.084
-
Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
Score: 0.185
-
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2024 05; 34(4):201-209.
Score: 0.178
-
Pain-related hospitalization and emergency room visit following initial analgesic prescription after outpatient surgery. Pharmacoepidemiol Drug Saf. 2024 02; 33(2):e5759.
Score: 0.178
-
Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents. J Clin Psychopharmacol. 2024 Mar-Apr 01; 44(2):124-132.
Score: 0.177
-
The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J Clin Psychiatry. 2023 Dec 20; 85(1).
Score: 0.176
-
Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
Score: 0.174
-
Trends in Repeat Opioid Analgesic Prescription Utilization for Acute Pain in Children: 2013-2018. Acad Pediatr. 2024 07; 24(5):776-782.
Score: 0.174
-
Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
Score: 0.173
-
Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
Score: 0.171
-
Utilization and Predictors of Adjuvant Metformin for Children and Adolescents on Mixed Receptor Antagonists (Second-Generation Antipsychotics). J Am Acad Child Adolesc Psychiatry. 2023 11; 62(11):1245-1255.
Score: 0.169
-
Association Between Initial Opioid Prescription Duration and 30-Day Risk of Receiving Repeat Opioid Among Children. Acad Pediatr. 2023 03; 23(2):416-424.
Score: 0.160
-
Association of Puberty Stage and Weight Status with Cardiometabolic Risk in Children and Adolescents Living on the Texas-Mexico Border. Metab Syndr Relat Disord. 2022 10; 20(8):440-450.
Score: 0.159
-
Risk of asthma exacerbation associated with opioid and nonopioid analgesic use in children with current asthma. J Manag Care Spec Pharm. 2022 Mar; 28(3):325-335.
Score: 0.155
-
Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
Score: 0.152
-
Utilization of opioid versus non-opioid analgesics in Medicaid and CHIP enrolled children with current asthma. Pharmacoepidemiol Drug Saf. 2021 Nov; 30(11):1520-1531.
Score: 0.149
-
Association of Primary and Behavioral Health Integrated Care Upon Pediatric Mental Disorder Treatment. Acad Pediatr. 2021; 21(7):1187-1194.
Score: 0.148
-
Association of the Healthcare Effectiveness Data and Information Set (HEDIS) Follow-Up Care Measures and Medication Adherence Among Medicaid Insured Children with ADHD. J Atten Disord. 2022 Feb; 26(3):370-376.
Score: 0.144
-
Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
Score: 0.133
-
Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
Score: 0.128
-
The association between geographic access to providers and the treatment quality of pediatric depression. J Affect Disord. 2019 06 15; 253:162-170.
Score: 0.127
-
Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
Score: 0.125
-
Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019 04; 15(4):395-403.
Score: 0.120
-
Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
Score: 0.119
-
Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
Score: 0.111
-
Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatr Serv. 2017 Jul 01; 68(7):681-688.
Score: 0.110
-
Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014 Dec; 24(10):551-61.
Score: 0.094
-
Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiol Drug Saf. 2014 Mar; 23(3):299-308.
Score: 0.089
-
The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. J Affect Disord. 2013 Sep 05; 150(2):424-9.
Score: 0.085
-
Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. Psychiatr Serv. 2015 Apr 01; 66(4):404-10.
Score: 0.024